• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Sets New Certificate of Confidentiality Application Process for Nonfederal Trials

FDA Sets New Certificate of Confidentiality Application Process for Nonfederal Trials

November 23, 2020

Sponsors of nonfederally funded clinical trials can request a certificate of confidentiality (CoC) that protects them from being compelled to disclose participants’ private information, according to a final FDA guidance released last week.

A CoC specifically prohibits an investigator or sponsor from releasing a participant’s identifiable, sensitive information — including biospecimens — to anyone not connected to the trial so that they cannot be compelled to disclose the information in any kind of legal proceeding or litigation.

However, it does not protect investigators or sponsors from any federal, state or local laws already on the books that require disclosure. The CoC also does not apply to information that is necessary for a participant’s medical treatment, released with the consent of the participant or used for the purposes of other scientific research conducted under federal human research subject protections.

While federally funded trials are required to have a CoC, trials not sponsored by a federal agency are not, but they may apply for one if they are conducting research regulated by the FDA, says the guidance.

Other entities involved in a trial, such as CROs or academic institutions, are also bound by CoCs, but the FDA recommends that only sponsors or sponsor-investigators submit requests for them to avoid duplicate requests.

The final guidance includes the same provisions as the draft released in November 2019 with the exception of two points suggested in public comments on the draft: clarification of the definition of “identifiable, sensitive information” and an additional paragraph noting that it is within a trial’s IRB authority to require a CoC as a condition of approval.

Read the final guidance at https://bit.ly/3pMzqLX.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing